Challenges of Pre-analytical Variables in Conventional Cytogenetics - A University Teaching Hospital Experience

Dr. Vidya Jha¹, Ajeesh G.A.², Akhil K.S.³

¹MD, MHA, Assistant Professor and Assistant Medical Administrator, Department of Cytogenetics, Amrita Institute of Medical Sciences, Kochi, India; ²BSc MLT, Lab technician, Department of Cytogenetics, Amrita Institute of Medical Sciences, Kochi, India; ³MSc Biotechnology, Junior Research Fellow, Department of Cytogenetics, Amrita Institute of Medical Sciences, Kochi, India

ABSTRACT

Introduction: Conventional Cytogenetics is an essential tool for the diagnosis of a neoplastic or premalignant condition and provides important prognostic and therapeutic information. The rate of unsuccessful karyotyping in hematological malignancies is reported between 10-20%.

Objective: To analyze the relationship between pre-analytical variables and associated failures with conventional karyotyping in hematological neoplasms.

Material and Methods: 1020 samples with suspected hematological malignancies received in the department of Cytogenetics from January 2018 to December 2019 were included in the study. Pre-analytical variables assessed included time from collection to sample processing, type of sample, diagnosis and sample cellularity. Statistical analysis was performed using Chi-square test to verify associations of variables with karyotyping.

Results: 86 (12%) out of 720 samples that were processed in less than 24 hours of time of collection showed an unsuccessful KT while 57/300 samples (19%) that were processed beyond 24 hours failed to yield any metaphase (p-value 0.003). 31/79 PVB (39%) and 112/941 BM (12%) were unsuccessful (p-value <0.001). 15/287 (06%) acute myeloid leukemia cases, 64/156 (41%) acute lymphoblastic leukemia cases, 12/109 (11%) myelodysplastic syndrome, 6/34 (18%) MDS/MPN cases, 11/338 (03%) MPN cases and 35/96 (36%) from the others category did not yield any metaphase for analysis (p value 0.015. 24/819 (03%) samples with cellularity >7 x 10³/µl and 119/201 (59%) samples with low cellularity being ≤7 x 10³/µl were unsuccessful (p-value <.001).

Discussion: Rate of unsuccessful karyotyping was 14% that was significantly associated with the time to process, nature of sample and cellularity.

Conclusion: Collection of an adequate and good quality sample is of paramount importance on which success of karyotyping of hematological malignancies depends.

Key Words: Pre-analytical variables, Karyotyping, Cytogenetics, Hematological malignancies

INTRODUCTION

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues incorporates cytogenetic and molecular genetics abnormalities.¹

Hematologic neoplasm is listed in the top ten malignancies worldwide and also one of the leading causes of mortality in patients with cancer. Almost 9% of all cancer cases diagnosed in a year are hematological malignancies.²³ Identification of clonal aberrations yields support in diagnosing malignant/premalignant diseases as well as gives important information regarding prognosis and therapy.⁴⁵ Therefore, conventional cytogenetic analysis is mandatory in the evaluation of suspected acute leukemia. It is one of the essential tools for classification of hematological malignancies, prognostication and treatment.⁶⁷ It is also seen that unsuccessful conventional karyotyping has a prognostic implication in hematological malignancies.⁸⁹¹⁰ The rate of unsuccessful karyotyping in hematological malignancies is reported between 10-20%. Successful karyotyping is affected by number of factors like nature of sample, time to process, collection method, cellularity of sample and processing methods.¹¹ The present study aims to analyze the
relationship between pre-analytical variables and associated failures with conventional karyotyping in hematological neoplasms.

**MATERIAL AND METHODS**

The archives of department of Cytogenetics were retrospectively reviewed from January 2018 to December 2019. Of the 4300 cytogenetic case records reviewed over a period of 2 years, 1020 samples of bone marrow and blood with suspected hematological malignancies were received over a period of 2 years. Along with clinical history and examination, peripheral blood counts, marrow morphology and immunophenotyping was done to come to a diagnosis. Molecular tests like JAK2 mutation, Ph chromosome etc. were done, wherever required. Final diagnosis was made based on WHO criteria. Bone marrow samples were cultured for 17 and 24 hours without mitogenic agents and harvested following standard protocols. The slides were air-dried and stained with G-Banding using Trypsin and Giemsa (GTG-banding). Twenty metaphases were analyzed and karyotypes were described according to the International System for Human Cytogenetic Nomenclature criteria.

**Pre-analytical parameters**

The following pre-analytical variables were noted:

1. Time from sample collection to initiation of processing in lab (more or less than 24 hours)
2. Material type (bone marrow or peripheral venous blood)
3. Sample cellularity (≥7 or ≤7 x 10⁹/µl)
4. Patient’s diagnosis (AML, ALL, MDS, MPN, CLL, MDS/MPN)

Statistical analysis was performed using Chi-square test to verify associations of variables with karyotyping. The data were analyzed using IBM SPSS software (Version 21). The level of significance for the statistical tests was 5% (p-value < 0.05).

**RESULTS**

Out of the 4300 cases received in Cytogenetics lab over a period of 2 years, 1020 samples with hematological malignancies were found. The mean patient age was 46 years (range 1 month – 84 years). There were 612 (60%) males and 408 (40%) females with a male : female ratio of 1.5. The diagnosis of 1020 cases as per the WHO criteria was as follows: myeloproliferative syndrome 338 (33%), acute myeloid leukemia 287 (28%), acute lymphoid leukemia 156 (15%), myelodysplastic syndrome 109 (11%), MDS/MPN 34 (03%) and Others like plasma cell disorder, chronic lymphoid leukemia etc 96 (09%).

Out of the 1020 samples, there were 941 (92%) bone marrow (BM) specimen and 79 (08%) peripheral venous blood (PVB) specimens. 720 (71%) samples had culture set up in less than 24 hours from their time of collection. 819 (80%) samples had cellularity more than 7x10⁹/µl. 143 (14%) samples out of 1020 failed to yield any metaphase on culture that precluded any cytogenetic analysis. The pre-analytical variables associated with unsuccessful or failed karyotype (KT) are shown in table 1. 86 (12%) out of 720 samples that were processed in less than 24 hours of time of collection showed an unsuccessful KT while 57/300 samples (19%) that were processed beyond 24 hours failed to yield any metaphase (p-value 0.003). 31/79 PVB (39%) and 112/941 BM (12%) were unsuccessful (p-value <0.001). 15/287 (06%) AML cases, 64/156 (41%) ALL cases, 12/109 (11%) MDS, 6/34 (18%) MDS/MPN cases, 11/338 (03%) MPN cases and 35/96 (36%) from the Others category did not yield any metaphase for analysis (p-value 0.015). 24/819 (03%) samples with cellularity ≥7 x 10⁹/µl and 119/201 (59%) samples with low cellularity being ≤7 x 10⁹/µl were unsuccessful (p-value <0.001).

**DISCUSSION**

Cytogenetic analysis remains one of the essential tools for classification of hematological malignancies, prognostication and treatment. WHO criteria for diagnosis of hematological malignancies includes cytogenetic abnormalities. However, despite its relevance, sometimes G-banding karyotyping fails to give results due to technical difficulties that yield poor mitotic index.

In the present study, 143/1020 (14%) samples did not yield any metaphase for analysis and therefore were categorized as Unsuccessful karyotyping (UK). This UK’s rate lies between the accepted range of UK reported in literature in case of hematological malignancy (10–20%). As per the guidelines, a minimum of 20 metaphases must be analyzed in the absence of any abnormality. It will help in excluding presence of 14% of any abnormal clone with 95% confidence. The remaining 877 samples, 810 (92.4%) yielded 20 metaphases, 35 samples (4%) had 10-20 which were categorized as ‘Incomplete karyotype’ and 32 (3.6%) had less than 10 metaphases which were labeled as ‘Insufficient karyotype’. In our lab, 88% of the samples (634/720) processed within 24 hrs of its time of collection were successful. We had a higher success rate with samples processed in less than 24 hrs (86/720, 12% UK) when compared to those that were processed after 24 hrs (57/300, 19%). Unlike the work done by Santos and his coworkers, it was statistically significant (p-value 0.003). As per the literature, it is recommended to send a sufficient quantity of BM (0.5–1 ml minimum), preferably within 24 h after aspiration (best is as soon as possi-
ble) to the Cytogenetics laboratory. Care should be taken to avoid delays in transport and exposure to extreme temperatures. Use of transport medium is also strongly recommended to minimize drying-out of the sample and to maintain the viability of the cells.\textsuperscript{4,14,15}

For hematological malignancies including myeloma, the specimen of choice for analysis is bone marrow. Peripheral venous blood should be used only if there is a significant level of circulating disease.\textsuperscript{16} In our study, we found that unsuccessful Karyotype was seen at a higher rate in PVB (39%) when compared to BM (12%). The nature of sample - PVB and BM showed a statistically significant difference (p-value <0.001) in the outcome of metaphase yield where PVB was found to be associated with UK. This is in concordance to reports published by other authors.\textsuperscript{6,17} PVB may yield informative results when the circulating blast cell percentage is higher than 10% and should be considered as an alternative where a BM sample or culture has proved inadequate. It is inappropriate for all diagnoses, like MDS, MPD (except chronic granulocytic leukemia and myelofibrosis) or pancytopenic AML.\textsuperscript{6,15} In cases of dry tap, for example myelofibrosis aspiration of BM is often unsuccessful because of considerable fibrotic changes and replacement of hemopoietic cell clusters onto reticulin and collagen fibers. In the study by Lozynskyy and his coworkers, BM and PVB samples from patients with myelofibrosis with cytogenetic analysis of un-stimulated PVB samples culture was unsuccessful in all 10 patients due to either insufficient quantity or quality of mitotic division. When they set up cell cultures of PVB leukocytes stimulated in vitro with G-CSF all 31 patients resulted in good metaphase with successful karyotyping.\textsuperscript{18} PVB may be used for hematological malignancies keeping in mind that the abnormal clone may not be identified in such specimens as frequently as in bone marrow.\textsuperscript{14} BM samples that have been contaminated with blood during aspiration might lack an adequate number of spontaneously dividing cells. Care should be taken to avoid hemodilution of the sample. For this reason, it is important that the cytogenetics laboratory receive the first few milliliters of the bone marrow tap.\textsuperscript{4,19}

In our study, the incidence of UK was highest (41%) for acute lymphoblastic leukemia followed by 18% in MDS/MPN and 6% in AML. Santos et al. reported a higher UK rate in AML (13.3%) and MDS (16.4%).\textsuperscript{6} In their study, Medeiros and his coworkers have reported an UK incidence in AML as 10%. Santos et al. reported a higher UK rate in AML. In our study, we found that highly cellular PVB had more UK. Out of the 3% of UK seen in samples with high cellularity, we found that highly cellular PVB had more failure rate (33%) than BM with higher cellularity (2.5%). This is similar to findings of Santos et al who reported UK in 3.9% of BM with high cellularity and 41.9% in PVB with high cellularity.\textsuperscript{6}

\section*{CONCLUSION}

Conventional cytogenetics provides support for a malignant or premalignant hematological condition and provides important prognostic and therapeutic information. It is helpful in predicting initial response to therapy, duration of remission and survival. Pre-analytical parameters impact the success of conventional cytogenetics. As per the present study, unsuccessful conventional karyotyping (14% in the present study) is directly related to pre-analytical parameters like time to process, nature of sample and cellularity. Therefore, bone marrow should be preferred for cytogenetics, samples should be transported to lab as soon as possible and correct volume of samples should be used to set up culture in order to get a better success rate. To conclude, the authors believe that collection of an adequate and good quality sample is of paramount importance on which success of karyotyping of hematological malignancies depends.

\section*{Acknowledgement}

Authors acknowledge the immense help received from the scholars whose articles are cited and included in references
of this manuscript. The authors are also grateful to authors / editors / publishers of all those articles, journals and books from where the literature for this article has been reviewed and discussed.

**Financial support** - Nil

**Conflict of interest** - Nil

### REFERENCES

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405. doi:10.1182/blood-2016-03-643544.

2. Prakash G, Kaur A, Malhotra P, Khadwal A, Sharma P, Suri V, et al. Current role of genetics in hematologic malignancies. Indian J Hematol Blood Transfus 2016;32:18-31.

3. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics,2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236.

4. Rack, K.A., van den Berg, E., Haferlach, C. et al. European recommendations and quality assurance for cytogenetic analysis of hematological neoplasms. Leukemia 33, 1851–1867 (2019). https://doi.org/10.1038/s41375-019-0378-z

5. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosomal aberrations and gene fusions in cancer. 2018. http://cgap.nci.nih.gov/Chromosomes/Mitelman

6. Santos MFM, Oliveira FCAC, Kishimoto RK, Borri D, Santos FPS, Campregher PV et al. Pre-analytical parameters associated with unsuccessful karyotyping in myeloid neoplasm: a study of 421 samples. Braz J Med Biol Res. 2019 Feb 14;52(2): e8194. doi: 10.1590/1414-431X20188194.

7. Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeier J, Harbott J, et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 2007; 46: 494–499. doi:10.1002/gcc.20433.

8. Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. Br J Haematol 2014; 164: 245–250. doi: 10.1111/bjh.12625.

9. Yang W, Stotler B, Sevilla DW, Emmons FN, Murty VV, Alobeid B, et al. FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes? Leuk Res 2010; 34: 420–425. doi: 10.1016/j.leukres.2009.09.013.

10. Cervera J, Solé F, Haase D, Luño E, Such E, Nomdedeu B, et al. Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes. In: Leukemia Research 2009; 33: Abstracts of the 10th International symposium on myelodysplastic syndromes, Patras (Greece) 6–9 May 2009. Abstract number: P030.

11. Watson MS. Quality assurance and quality control in clinical cytogenetics. In: Dracopoli NC, Haines JL, Korf BR, Morton CC, Seidman CE, Seidman JG, Smith DR (Ed), Current Protocols in Human Genetics. New York: John Wiley; 2007. p 8.2.1–8.2.9.

12. Shaffer LG, Tommerup N ISCN 2005, an international system for human cytogenetic nomenclature (2005), S. Karger AG, Basel (2005) ISBN 3-8055-8019-3.

13. Hook EB. Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use. Am J Hum Genet. 1977;29:94–97.

14. Mikhail FM, Heerema NA, Rao KW, Burnside RD, Cherry AM, Cooley LD. Section E6.1-6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow-acquired chromosomal abnormalities. Genet Med 2016; 18: 635–642, doi: 10.1038/gim.2016.50.

15. Potter AM, Watmore A. Cytogenetics in myeloid leukaemia. In: Rooney DE and Czepulkowski BH (Ed). Human Cytogenetics: A Practical Approach. Volume 2: Malignancy and Acquired Abnormalities. Second edition. Oxford: IRL Press at Oxford University Press, 1992. p28.

16. Cherry AM, Slovak ML, Campbell LJ, Chun K, Eclache V, Haase D, et al. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? Leuk Res. 2012;36:832–40.

17. Hussein K, Ketterling RP, Hulshizer RL, Kuffel DW, Wiktor AE, Hanson CA, et al. Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. Eur J Haematol 2008; 80: 318–321, doi: 10.1111/j.1600-0609.2007.01021.x.

18. Lozynska RR, Lozynska MR, Hontar YV, Huleyuk NL, Malysak ZV, Novak VL. Study of cytogenetic abnormalities in G-CSF stimulated peripheral blood cells and non-stimulated bone marrow cells of patients with myelofibrosis. Exp Oncol 2016; 38: 40–44.

19. Gerssen SL and Keagle MB (Ed). The principles of clinical cytogenetics. Second edition. New Jersey: Humana Press, 2005, doi:10.1385/1592598331.

20. Stevens-Kroef MJ, Olde Weghuis D, Eldrissi-Zaynoun N, Van der Reijden B, Cremers EMP, Alhan C, et al. Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial. Genes Chromosomes Cancer 2017; 56: 524–534, doi: 10.1002/gcc.22455.

21. Arsham MS, Barch MJ, Lawce HJ. The AGT Cytogenetics Laboratory Manual. Fourth edition. Hoboken, New Jersey: Wiley-Blackwell, 2017, doi: 10.1002/9781119061199.

22. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.

23. Swansbury J. Cytogenetic studies in hematologic malignancies: an overview. In: Swansbury J (Ed). Cancer Cytogenetics: methodology and protocols. First edition. New Jersey: Humana press, 2003. p 13–17.
Table 1: Pre-analytical variables and association with karyotype success

| Variable                  | Total | Karyotype | p-Value |
|---------------------------|-------|-----------|---------|
|                           |       | Successful| Unsuccessful|
|                           |       | n (%)     | n (%)    |
|                           |       |           |          |
| Time to process           |       |           |          |
| <24h                      | 720   | 634       | 88       | 86 | 12 | 0.003* |
| >24h                      | 300   | 243       | 81       | 57 | 19 |         |
| Type of sample            |       |           |          |
| Bone marrow               | 941   | 829       | 88       | 112 | 12 | <0.001* |
| Peripheral venous blood   | 79    | 48        | 61       | 31 | 39 |         |
| Diagnosis                 |       |           |          |
| AML                       | 287   | 272       | 94       | 15 | 6  |         |
| ALL                       | 156   | 92        | 59       | 64 | 41 |         |
| MDS                       | 109   | 97        | 89       | 12 | 11 |         |
| MDS/MPN                   | 34    | 28        | 82       | 6  | 18 |         |
| MPN                       | 338   | 327       | 97       | 11 | 3  |         |
| OTHERS                    | 96    | 61        | 64       | 35 | 36 |         |
| Cellularity               |       |           |          |
| >7 x 10^3/µl              | 819   | 795       | 97       | 24 | 3  | <0.001* |
| ≤7 x 10^3/µl              | 201   | 82        | 41       | 119 | 59 |       |
| TOTAL                     | 1020  | 877       | 86       | 143 | 14 |       |

*p-Value <0.05